MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$202,631K
Proceeds from the
exercise of stock options
$502K
Net cash provided by
financing activities
$203,063K
Canceled cashflow
$70K
Net decrease in cash
and cash...
-$28,753K
Canceled cashflow
$203,063K
Stock-based compensation
expense
$12,520K
Accrued expenses
$6,667K
Accounts payable
$2,141K
Sales and maturities
of short-term and...
$201,706K
Payment of deferred
financing costs
$70K
Net cash used in
operating activities
-$160,588K
Canceled cashflow
$21,328K
Net cash used in
investing activities
-$71,228K
Canceled cashflow
$201,706K
Net loss
-$166,308K
Prepaid expenses and
other current assets
$12,561K
Amortization/accretion of bond
discounts/premiums
-$3,026K
Operating lease
liabilities
-$21K
Purchase of short-term
and long-term...
$272,934K
Back
Back
Cash Flow
source: myfinsight.com
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)